国循発ベンチャー、1400万ドルを調達 パー・セラピューティクス、PAHの治療法開発へ
MediaPortfolio Companies
国循発ベンチャー、1400万ドルを調達 パー・セラピューティクス、PAHの治療法開発へ
July 29, 2025
Press Release
Portfolio Companies
Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines
Cambridge, Mass., September 2, 2026

Press Release
Portfolio Companies
Crystalys Therapeutics Closes $130 Million Series B Funding to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
San Diego, July 23, 2026
